GUANGZHOU, China, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that analytical validation data of its fully-automated NGS library preparation platform, Magnis BR, will be presented at the Association for Molecular Pathology (AMP) 2020 annual meeting, in a platform presentation (abstract number TT04) on Thursday, November 19, 2020. Link to conference schedule here.

Read more:
Burning Rock to Present Validation Data of Magnis BR at the AMP Annual Meeting

REGULATED INFORMATION

Here is the original post:
Bone Therapeutics Provides Third Quarter 2020 Business Update

The first presentation of new data characterizing the anti-ChemR23 antibody was at the FOCIS Virtual Annual Meeting held October 28-31, 2020 The first presentation of new data characterizing the anti-ChemR23 antibody was at the FOCIS Virtual Annual Meeting held October 28-31, 2020

Here is the original post:
OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation

Montrouge, France, October 30, 2020

Read more from the original source:
DBV Technologies Reports September 30, 2020 Cash Position

Oslo, Norway, 30 October 2020

Read more:
Vistin Pharma ASA: Third quarter and YTD 2020 financial results

30 October 2020 - Financial report for the period 1 January 2020 to 30 September 2020

Original post:
Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates (CER) in the first nine months of 2020

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, will host a live virtual R&D Day Webinar, with presentations by key opinion leaders in hematology, today from 1:00 – 3:00 pm Eastern Time.

Read more:
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today

Biotechs get scalable early to late phase clinical offering from Cromos Pharma and Avance Clinical collaboration in Australia and Europe Biotechs get scalable early to late phase clinical offering from Cromos Pharma and Avance Clinical collaboration in Australia and Europe

Read the original:
Euro-Australian collaboration offers scalable solutions for biotech: announced at Bio-Europe 2020

October 30, 2020 – announcement no. 26

Original post:
Lise Mortensen assumes responsibility as new CFO

Data supporting antibody and intrabody candidates that selectively target toxic TDP-43 while preserving normal protein highlighted Data supporting antibody and intrabody candidates that selectively target toxic TDP-43 while preserving normal protein highlighted

More:
ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium

TORONTO and CHICAGO and MONTREAL, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has entered into a consulting agreement (the “Consulting Agreement”) with Westmount Capital (“Westmount”) to provide European investor relations services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange and applicable legislation. Under the terms of the Consulting Agreement, Westmount will receive C$5,000 per month for an initial trial period of 3 months, commencing on November 1, 2020, following which a possible extension will be reviewed by the Company. The services contemplated under the Consulting Agreement include introducing the Company to various institutional investors, fund managers, family offices and other potential investors throughout Europe.

Read this article:
Medexus Announces Engagement of Westmount Capital and Equity Incentive Grants to Insiders

NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter and nine months ended September 30, 2020 and to provide a business update.

Read this article:
CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

Largest studies in POMC and LEPR deficiency obesities demonstrate that treatment with setmelanotide reduced body weight and hunger Largest studies in POMC and LEPR deficiency obesities demonstrate that treatment with setmelanotide reduced body weight and hunger

Visit link:
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology

Liposuction is a surgical procedure to remove extra fat from your body. It started in the 1980s and has become one of the most popular plastic surgeries in the US. An estimated 258,000 Americans got it in 2018.

Today, you can expect to pay around $3,500 for liposuction and most health insurance plans won't cover the cost. But if you're willing to pay the price, liposuction is a relatively safe and quick procedure that can help you shed fat that diet and exercise can't.

Some of the most common places to have fat removed are the belly, thighs, buttocks, arms, back, the upper neck just under the chin, and jawline/jowls.

Advertisement

Then, surgeons will often inject into the area of operation a solution containing a mix of saline solution, a numbing medicine, and medicine the decreases bleeding. This is to help the skin and fat separate from important structures like muscles and blood vessels so they aren't damaged during the suctioning process.

After liposuction, your surgeon will likely recommend you wear a temporary band or brace over the area of operation to help the skin heal. The band or brace also helps prevent fluid from building up in the area of operation where the fat was removed, between the skin and deeper structures like muscles and blood vessels.

Whether you are awake or asleep during liposuction, you shouldn't feel any pain during the procedure, says Marco A. Pelosi II, MD, a cosmetic surgeon with experience performing liposuction procedures. The recovery, also, should be a relatively mild process.

Ongoing pain near the area where the cannula was inserted is a risk of liposuction, and if the pain grows or pain killers don't help, you should tell your surgeon.

According to the Cleveland Clinic, you should not use liposuction as a weight loss alternative. It recommends that if you want to lose weight, you should first try diet and exercise, then use liposuction to take care of more stubborn areas like the chin or belly fat.

There are some important safety tips to look for when choosing a liposuction provider.

Pelosi says that doctors should also do blood work testing and medical clearances before a liposuction procedure to ensure your safety. These tests are to make sure you can safely undergo general anesthesia without complication. If, for example, you have an infection or are pregnant, you may not qualify for the surgery.

Read the original:
What is liposuction? How the procedure works and how painful it is - Business Insider India

Blood cancer is a disorder that affects the production as well as the normal functioning of blood cells. The process of normal blood cell development is disturbed because of the uncontrolled growth of abnormal blood cells. These abnormal or cancerous cells disrupt the normal functions of blood components such as preventing bleeding and defending infections.

Blood Cancer (Haematopoietic malignancies) is one of the top 10 cancers in India and as per the latest Cancer Report of ICMR, it is estimated that by 2025 nearly 1.38 lakh people would be affected. Currently, around 1.25 lakh people are suffering from the disease which constitutes 9% of total cancers in the country.

While speaking about blood cancer, Dr Divya Bansal, Consultant - Clinical Hematology and Stem Cell Transplant, HCMCT Manipal Hospitals, New Delhi, said, "Blood is a liquid medium present throughout the body and not confined to a defined area, which makes blood cancers and their treatment very different from solid-organ cancers. There is a limited role of surgery and radiation therapy in the treatment of blood cancers, as they are thermosensitive."

She continued, "Chemotherapy treatment for blood cancers is much more intense in comparison to solid cancers and hence, their side effects. Also, the staging of blood cancers is very different from solid cancers and concept of metastasis is not applicable for blood cancers."

"In the case of blood cancers, prognostic risk stratification is important. Bone marrow transplant has a limited role in solid cancers but remains the curative treatment for blood cancers. This difference has actually led to the development of a completely different speciality for treatment of blood cancers i.e. Haemato-oncology, all over the world," Dr Divya Bansal added.

Meanwhile, in order for us to understand the types of blood cancers, its symptoms and treatment, Dr Divya Bansal carefully explained each one and helped us list them out.

Take a look.

Types of blood cancers

Leukaemia

This is caused by the fast production of abnormal white blood cells, and these abnormal are seen in blood and the bone marrow. A large number of abnormal WBCs are unable to defend infections.

Lymphoma

This is a type of blood cancer that involves the lymphatic system. Abnormal lymphocytes turn into lymphoma cells that multiply and get accumulated in the lymph nodes. Gradually, these cancer cells impair the immune system.

Myeloma

This affects the plasma cells, the cells that produce antibodies against disease in the body. Myeloma cells disturb the normal development of antibodies and make the body susceptible to infection.

Symptoms

- Fever- Weight loss- Loss of appetite- Bony pains- Bleeding from any sites- Generalised weakness and fatigue- Night sweats- Nodular swelling around the neck, axilla or groin- Abdominal swelling

Diagnosis

One can get the disease diagnosed with the help of a blood test, bone marrow aspiration, and biopsy. In cases of lymphoma, one must opt for a lymph node biopsy. Other options include PET-CT, specialized tests such as Flowcytometry or Immunohistochemistry, Fluorescent in situ hybridization (FISH), Karyotyping and Next-generation sequencing (NGS) which is the latest technique of diagnosing and risk stratification of blood cancers.

Treatment

Chemotherapy

An oral or injectable drug that travels in the bloodstream throughout the body and kills the cancer cells. It damages cancer cells and stops division and growth of it, leading to their death.

Immunotherapy

It refers to agents that use the bodys immune system to help fight diseases such as blood cancer. It can work directly with your bodys immune system to stop or slow the growth of cancer cells. Biologic therapies include substances made by the body or in a lab. Cytokines, Gene therapy, and Immunomodulators, and Monoclonal antibodies are the main types of immunotherapy.

Targeted therapy

Therapies that target a certain genetic mutation known to occur in a specific blood cancer is called targeted therapy. Here, we target a protein that is present in cancer cells due to mutation. As soon as a mutation is identified, we can develop a treatment to target that target. Destroying cancer cells is the main aim of this therapy.

Bone Marrow Transplantation (BMT)

It is a procedure where a damaged or non-functional bone marrow cells are replaced by healthy multipotent hematopoietic stem cells.

Overall, BMT remains the only curative treatment for most of the blood cancers. There are two types of bone marrow transplant procedure used in the treatment of blood cancers -- Autologous BMT, when patient's own stem cells are infused back after high dose chemotherapy, and, Allogenic BMT, when the source of stem cells is a healthy donor, either related or unrelated.

A few blood cancers if treated promptly and effectively can be managed well and even cured.

Examples of blood cancers which can be cured include Acute Promyelocytic leukaemia, Chronic myeloid leukaemia, Hairy cell leukaemia, and Paediatric Acute lymphoblastic leukaemia.

View post:
Know all about types of blood cancer, its symptoms, diagnosis and treatment - DNA India

The Global Hematopoietic Stem Cell Transplantation (HSCT) Market report offers key insights into the worldwide Hematopoietic Stem Cell Transplantation (HSCT) market. It presents a holistic overview of the market, with an in-depth summary of the markets leading players. The report is inclusive of indispensable information related to the leading competitors in this business sector and carefully analyzes the micro- and macro-economic market trends. The latest report specializes in studying primary and secondary market drivers, market share, the leading market segments, and comprehensive geographical analysis. Vital information about the key market players and their key business strategies, such as mergers & acquisitions, collaborations, technological innovation, and trending business policies, is one of the key components of the report.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3627

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

China Cord Blood Corp, Pluristem Therapeutics Inc., CBR Systems Inc CellGenix Technologie Transfer GmbH, Cryo-Save AG Kite Pharma Inc., Regen Biopharma Inc., ViaCord Inc., BiolineRx, Cynata Therapeutics, Cesca Therapeutics Inc, Lonza Group Ltd, TiGenix N.V., Bluebird Bio, Cellular Dynamics International, and Escape Therapeutics Inc., among others.

Furthermore, our market analysts have drawn focus to the significant impact of the COVID-19 pandemic on the global Hematopoietic Stem Cell Transplantation (HSCT) market and its key segments and sub-segments. The grave aftereffects of the pandemic on the global economy, and subsequently, on this particular business sphere, have been enumerated in this section of the report. The report considers the key market-influencing parameters, delivering a detailed future impact assessment. The Hematopoietic Stem Cell Transplantation (HSCT) market has been devastated by the pandemic, which has culminated in drastic changes to the market dynamics and demand trends.

In market segmentation by types of Hematopoietic Stem Cell Transplantation (HSCT), the report covers-

In market segmentation by applications of the Hematopoietic Stem Cell Transplantation (HSCT), the report covers the following uses-

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3627

Moreover, the research report thoroughly examines the size, share, and market volume of the Hematopoietic Stem Cell Transplantation (HSCT) industry in the historical years to forecast the same valuations over the forecast duration. It offers exhaustive SWOT analysis, Porters Five Forces analysis, feasibility analysis, and investment return analysis of the Hematopoietic Stem Cell Transplantation (HSCT) market, assessed using certain effective analytical tools. The report also provides strategic recommendations to market entrants to help them navigate around the entry-level barriers.

The global Hematopoietic Stem Cell Transplantation (HSCT) market is geographically categorized into:

The following timeline is considered for market estimation:

Historical Years: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Years: 2020-2027

Key Coverage of the Report:

To read more about the report, visit@ https://www.reportsanddata.com/report-detail/hematopoietic-stem-cell-transplantation-hsct-market

Thank you for reading our report. For further information or queries regarding the report, please get in touch with us. Our team will make sure your report is tailored according to your requirements.

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web: http://www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail: [emailprotected]

Read more from the original source:
How Hematopoietic Stem Cell Transplantation (HSCT) Market Will Dominate In Coming Years? Report Covering Products, Financial Information,...

TipRanks

America goes to the polls on Tuesday (well, actually, America has been early voting for a few weeks, now), and while Democrat Joe Biden has a solid lead in the polls, there is some of evidence that President Trump may still win a second term. Finally, with all of the early voting, mass absentee ballots, and possible extended counting deadlines, we might not know on Tuesday night who the winner is.Its a situation made of uncertainty, and financial markets dont like that. Which brings us to dividend stocks. Investors want a pad, something to protect their portfolio in case of a market drop, and dividends offer just that. These profit-sharing payments to stockholders provide a steady income stream, that typically stays reliable even in a modest downturn. Wall Streets analysts have been doing some of the footwork for us, pinpointing dividend-paying stocks that have kept up high yields, at least 8% to be exact. Opening up theTipRanks database, we examine the details behind those payments to find out what else makes these stocks compelling buys.Altria Group, Inc. (MO)Well start with Altria Group, the tobacco company best known for its iconic Marlboro cigarettes. Altria, like many of the so-called sin stocks, is one of the markets dividend champions, with a long history of reliable, high-yielding payments. The company has benefited from a psychological quirk of human nature during such a wild year as 2020: People will hunker down if necessary, but they wont give up their small pleasures.Cigarettes are exactly that, and even though overall smoking rates have been declining in recent years, Altria saw stable financial results in the last few quarters. The first and second quarters both showed $1.09 in earnings, well above the 97 cents expected in Q1 and modest beat against Q2s $1.06 forecast. Revenues hit $5.06 billion in Q2, in-line with the two previous quarters.Looking ahead, analysts expect Altria to post $1.15 per share in earnings on $5.5 billion in revenues when it reports Q3 results. That report is due out tomorrow morning. Meeting those results will help Altria maintain its dividend although the company has a long-standing, very public, commitment to do just that. Altria has kept its dividend reliable for the past 12 years, and for the last payment, made it September, the company even slightly raised the payout by 2.4%. The current dividend is 86 cents per common share, or $3.44 annualized, and yields an impressive 8.8%.Looking at Altria in the lead-up to the Q3 report, Deutsche Bank analyst Stephen Powers writes, [We] are positively biased on company fundamentals as we approach MO's results next weekreinforced by healthy scanned channel demand intraquarter across MO's core tobacco businesses, with particular strength in cigarettes driven by the Marlboro brand we believe continued operational execution in its core business will enable MO to more credibly position itself as a stable core tobacco investmentPowers rates the stock as a Buy, and his $51 price target implies a 37% upside for the coming year. (To watch Powers track record, click here)Overall, Altria has a Moderate Buy rating from the analyst consensus, based on 3 Buys and 2 Holds set in recent weeks. The stocks current share price is $37.04, and the average price target of $46 suggests a 24% one-year upside. (See MO stock analysis on TipRanks)American Finance Trust (AFIN)Next on our list is a Real Estate Investment Trust, a REIT. These companies are known for their high dividends, a fact resulting from a quirk of tax regulation. REITs are required to return a certain percentage of profits directly to shareholders, and dividends are one of the surest means of compliance. AFIN, which focuses its portfolio on single- and multi-tenant service-retail properties, is typical for its niche.And its niche has been solid. AFIN boasts major companies like Home Depot, Lowes, and Dollar General among its top ten tenants, and announced earlier this month that it has collected over 91% of its third quarter rents. Looking ahead to Q3 results next week, EPS is expected at 23 cents, a 15% increase from Q2. The company offers a monthly dividend, at a rate of 7.1 cents per common share, instead of the more common quarterly payments. The monthly format allows some flexibility in managing adjustments to the payout rate; in April, AFIN reduced the dividend from 9 cents to 7.1 as part of efforts to manage the corona crisis effects on business. The current payment annualizes to 85.2 cents per share, and yields a robust 14.7%. This is more than 7x higher than the average dividend yield found among S&P 500 companies.B. Riley analyst Bryan Maher notes the difficulties that AFIN has faced, as a property owner and manager during an economic downturn, but is confident in the companys ability to meet the challenges.Like most REIT's, AFIN has been impacted by the COVID-19 pandemic, which is not surprising given its portfolio has a large number of service retail assets. However, 71% of the portfolio is necessity-focused retail, with the balance being distribution and office properties. As such, AFIN collected 84% of cash rents due in 2Q20, including 96% of the cash rent due from its top 20 tenants. Cash rent collection for July improved to 88%. AFIN has been proactive in working with certain tenants to negotiate rent deferrals/credits Maher noted. To this end, Maher rates AFIN stock a Buy, and gives it a $10 price target. At current trading levels, this implies a strong one-year upside potential of 76%. (To watch Mahers track record, click here)AFIN is priced at $5.69, and its average target matches Mahers, at $10. The stock has a Moderate Buy from the analyst consensus, based on an even split between Buy and Hold reviews. (See AFIN stock analysis on TipRanks)Golub Capital BDC (GBDC)Last but not least is Golub Capital, a business development company and asset manager. Golub works with middle market companies, providing solutions for financing and lending. The company boasts a market cap of $2.2 billion, as well as over $30 billion in capital under management.In the months since the corona virus crisis hit the economy, Golub has seen a depressed share price and high volatility in its earnings. The stock is down 28% year-to-date. Earnings, which collapsed in 4Q19, have been bouncing in 2020. The first quarter showed 33 cent per share, while the Q2 figure came in at 28 cents. Looking ahead, the forecast expects a repeat of the second quarter EPS figure, 28 cents. Revenues have been just as volatile; the first quarter saw a deep net loss, but Q2 saw the top line bounce back to $145 million. This was the highest quarterly revenue figure in the past year.Golub believes in keeping up the dividend for investors, offering not only a reliable regular payment but also periodic special dividends. The company adjusted the payment earlier this year, both to keep it affordable during the coronavirus crisis and to keep the yield from getting too high. The result was a 12% cut, making the current payment 29 cents per common share quarterly. This still gives a high yield of 9.16%, which compares well to the 2.5% average found among finance sector peers.Finian OShea, from Well Fargo, notes that Golub has recently announced a $2 billion unsecured debt issue, a move that gives the company plenty of liquidity in a difficult time. He writes, GBDC isnt paying a hefty premium for unsecureds to begin with... We think the improved flexibility and longer tenor of unsecureds make them an attractive addition to the right side of the balance sheet, and see it as a vote of confidence in GBDCs underlying portfolio.OShea reiterates his Overweight (i.e. Buy) rating on this stock. His price target, at $13.50, indicates room for a modest 6% upside. (To watch OSheas track record, click here)Like AFIN above, Golub Capital has a Moderate Buy consensus rating, with 1 each Buy and Hold reviews. The stocks average price target matches OSheas, at $13.50. (See Golubs stock analysis at TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Here is the original post:
Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional...

GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has signed a research initiative related to its AIM nanoparticle technology with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.

City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001. The cancer center will leverage both patient samples from the ongoing NexImmune Phase 1/2 clinical study of NEXI-001 in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic stem cell transplantation and the center’s tumor repository bank of primary leukemia samples, one of the largest collections in the world, to drive the research.

NEXI-001 is a cellular product candidate that contains populations of naturally occurring CD8+ T cells directed against multiple antigen targets for AML, and it is the first clinical product generated by the Company’s AIM nanoparticle technology.

NexImmune has developed a unique and versatile technology platform that lends itself very effectively to important areas of ongoing research in the field of AML,” said Guido Marcucci, M.D., Chair and Professor with City of Hope’s Department of Hematologic Malignancies Translational Science. Our collective goal is to translate future research findings into new, more effective T cell immunotherapies to the benefit of these very difficult to treat patients.”

A key objective of the research will focus on the identification of new antigen targets that are expressed on both leukemic blasts as well as leukemic stem cells, and those which represent survival proteins to both. Once identified, these antigen targets will be loaded on NexImmune AIM-nanoparticles to expand antigen-specific CD8+ T cells, and evaluated in pre-clinical models for anti-tumor potency, tumor-specific killing, and response durability.

In addition, the research initiative will aim to further understand different mechanisms of tumor escape, such as tumor antigen and human leukocyte antigen (HLA) downregulation due to immune pressure.

Research between NexImmune and City of Hope will inform a scientific understanding of how the immune system can address certain tumor escape mechanisms to more effectively fight aggressive cancers like AML, and how this might be accomplished with NexImmune’s AIM technology and T cell products,” said Monzr Al Malki, M.D., Director of City of Hope’s Unrelated Donor BMT Program and Haploidentical Transplant Program and an Associate Clinical Professor with Department of Hematology and Hematopoietic Cell Transplantation. Based on our current clinical experience with this technology, we’re excited to learn what more this research will tell us.”

City of Hope is a world-class clinical research institution that has built one of the largest banks of leukemia samples in the world,” said Han Myint, M.D., NexImmune Chief Medical Officer. The depth of expertise that Drs. Marcucci, Al Malki and their team bring to this research initiative will help NexImmune continue to develop innovative products that can help patients with AML and other hard-to-treat cancers.”

City of Hope is a leader in bone marrow transplantation . More than 16,000 stem cell and bone marrow transplants have been performed at City of Hope, and more than 700 are performed annually. City of Hope’s BMT program is the only one in the nation that has had one-year survival above the expected rate for 15 consecutive years, based on analysis by the Center for International Blood and Marrow Transplant Research.

About NexImmune NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM technology is designed to generate a targeted T cell-mediated immune response and is initially being developed as a cell therapy for the treatment of hematologic cancers. AIM nanoparticles (AIM-np) act as synthetic dendritic cells to deliver immune-specific signals to targeted T cells and can direct the activation or suppression of cell-mediated immunity. In cancer, AIM-expanded T cells have demonstrated best-in-class anti-tumor properties as characterized by in vitro analysis, including a unique combination of anti-tumor potency, antigen target-specific killing, and long-term T cell persistence. The modular design of the AIM platform enables rapid expansion across multiple therapeutic areas, with both cell therapy and injectable products.

NexImmune’s two lead T cell therapy programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to > 3 prior lines of therapy, respectively. The Company’s pipeline also has additional preclinical programs, including cell therapy and injectable product candidates, for the treatment of oncology, autoimmune disorders, and infectious diseases.

For more information, visit http://www.neximmune.com.

Media Contact: Mike Beyer Sam Brown Inc. Healthcare Communications 312-961-2502 mikebeyer@sambrown.com

Investor Contact: Chad Rubin Solebury Trout +1-646-378-2947 crubin@soleburytrout.com

See original here:
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia - Stockhouse

The report on Global Orthopedic Regenerative Medicine Market is a dependable point of reference heralding high accuracy business decisions on the basis of thorough research and observation by seasoned research professionals at CMI Research. The report on global Orthopedic Regenerative Medicine market evidently highlights the causal factors such as demand analysis, trend examination, and technological milestones besides manufacturing activities that have been systematically touched upon to instigate systematic growth projection.

This CMI Research report on global Orthopedic Regenerative Medicine market systematically studies and follows noteworthy progresses across growth trends, novel opportunities as well as drivers and restraints that impact growth prognosis.

Free Sample Report + All Related Graphs & Charts @:https://www.coherentmarketinsights.com/insight/request-sample/3566

Which market players and aspiring new entrants may witness seamless entry?

Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Predicting Scope: Global Orthopedic Regenerative Medicine Market, 2020-2027

Elaborate research proposes global Orthopedic Regenerative Medicine market is likely to experience an impressive growth through the forecast span, 2020-2027, ticking a robust CAGR of xx% USD. The Orthopedic Regenerative Medicine market is anticipated to demonstrate a whopping growth with impressive CAGR valuation. The Orthopedic Regenerative Medicine market is also likely to maintain the growth spurt showing signs of steady recovery.

For appropriate analysis of all the market relevant information as well emerging trends and historical developments in the Orthopedic Regenerative Medicine market, CMI Research has referred to various primary and secondary research practices and contributing factors.

Regional Overview: Global Orthopedic Regenerative Medicine Market

The report specifically sheds light upon note-worthy business discretion, popular trends investment probabilities aligning with budding opportunities as well as breakthrough developments in policies and monetary inclination echoing investor preferences in Orthopedic Regenerative Medicine space.

Competitive Landscape: Global Orthopedic Regenerative Medicine Market

Further in the report, readers are presented with minute details pertaining to significant company profiles, product development, on pricing, production and vital information on raw material and equipment developments also form crucial report contents in this CMI Research report.

Have Any Query? Ask Our Expert @: https://www.coherentmarketinsights.com/insight/request-customization/3566

Segmentation Based on Orthopedic Regenerative Medicine Market Types:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Global Orthopedic Regenerative Medicine Market Size & Share, By Regions and Countries/Sub-regions:

Asia Pacific: China, Japan, India, and Rest of Asia Pacific

Europe: Germany, the UK, France, and Rest of Europe

North America: the US, Mexico, and Canada

Latin America: Brazil and Rest of Latin America

Middle East & Africa: GCC Countries and Rest of Middle East & Africa

The regional analysis segment is a highly comprehensive part of the report on the global Orthopedic Regenerative Medicine market. This section offers information on the sales growth in these regions on a country-level Orthopedic Regenerative Medicine market.

The historical and forecast information provided in the report span between2020 and 2027. The report provides detailed volume analysis and region-wise market size analysis of the market.

Report Investment, a Priority: Explains CMI Research

This report also helps market participants to organize R&D activities aligning with exact market requirements

The report resonates critical findings on decisive factors such as downstream needs and requirement specifications as well as upstream product and service development

The report aids in reader comprehension of the market based on dual parameters of value and volume.

This CMI Research initiated research output on Orthopedic Regenerative Medicine market is a ready-to-refer handbook of noteworthy cues for easy adoption by market players and stakeholders

CMI Research skillfully underpins a vivid segment analysis of the global Orthopedic Regenerative Medicine market, rendering appropriate inputs about the revenue generation capabilities of each segment.

Buy this research report @: https://www.coherentmarketinsights.com/insight/buy-now/3566

Thanks for reading our report. If you have any further questions, please contact us. Our team will provide you with the report tailored to your needs.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702Email:[emailprotected]Web:https://www.coherentmarketinsights.com/

Visit link:
Covid-19 Impact On Orthopedic Regenerative Medicine Market 2020 Future Development, Manufacturers, Trends, Share, Size And Forecast to 2027 |...

This article was originally published here

N Engl J Med. 2020 Oct 27. doi: 10.1056/NEJMoa2026834. Online ahead of print.

ABSTRACT

BACKGROUND: Adult-onset inflammatory syndromes often manifest with overlapping clinical features. Variants in ubiquitin-related genes, previously implicated in autoinflammatory disease, may define new disorders.

METHODS: We analyzed peripheral-blood exome sequence data independent of clinical phenotype and inheritance pattern to identify deleterious mutations in ubiquitin-related genes. Sanger sequencing, immunoblotting, immunohistochemical testing, flow cytometry, and transcriptome and cytokine profiling were performed. CRISPR-Cas9-edited zebrafish were used as an in vivo model to assess gene function.

RESULTS: We identified 25 men with somatic mutations affecting methionine-41 (p.Met41) in UBA1, the major E1 enzyme that initiates ubiquitylation. (The gene UBA1 lies on the X chromosome.) In such patients, an often fatal, treatment-refractory inflammatory syndrome develops in late adulthood, with fevers, cytopenias, characteristic vacuoles in myeloid and erythroid precursor cells, dysplastic bone marrow, neutrophilic cutaneous and pulmonary inflammation, chondritis, and vasculitis. Most of these 25 patients met clinical criteria for an inflammatory syndrome (relapsing polychondritis, Sweets syndrome, polyarteritis nodosa, or giant-cell arteritis) or a hematologic condition (myelodysplastic syndrome or multiple myeloma) or both. Mutations were found in more than half the hematopoietic stem cells, including peripheral-blood myeloid cells but not lymphocytes or fibroblasts. Mutations affecting p.Met41 resulted in loss of the canonical cytoplasmic isoform of UBA1 and in expression of a novel, catalytically impaired isoform initiated at p.Met67. Mutant peripheral-blood cells showed decreased ubiquitylation and activated innate immune pathways. Knockout of the cytoplasmic UBA1 isoform homologue in zebrafish caused systemic inflammation.

CONCLUSIONS: Using a genotype-driven approach, we identified a disorder that connects seemingly unrelated adult-onset inflammatory syndromes. We named this disorder the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. (Funded by the NIH Intramural Research Programs and the EU Horizon 2020 Research and Innovation Program.).

PMID:33108101 | DOI:10.1056/NEJMoa2026834

Read the original post:
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease - DocWire News